Compound: Triciribine
SMILES: O1[C@@H](n2c3ncnc4c3c(c2)C(=NN4C)N)[C@H](O)[C@@H]([C@H]1CO)O
InChIKey: HOGVTUZUJGHKPL-HTVVRFAVSA-N
Synonyms: Triciribine, 35943-35-2, Pentaazacentopthylene, Triciribina, Triciribinum, NSC 154020, NSC-154020, 2421HMY9N6, 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-, CHEBI:65310, 3-Amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene, 5-methyl-1-(beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine, 6-ARPPP, RefChem:933360, 6-amino-4-methyl-8-(beta-D-ribofuranosyl)-(4H,8H)pyrrolo(4,3,2-de)pyrimido(4,5-c)pyridazine, 2-(5-amino-7-methyl-2,6,7,9,11-pentaazatricyclo(6.3.1.0^(4,12))dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol, 3-amino-1,5-dihydro-5-methyl-I-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene, Tricyclic nucleoside, Triciribine [INN], Tricirbine, BRN 1171593, TCN, (2R,3R,4S,5R)-2-(3-amino-5-methyl-1,4,5,6,8-pentaazaacenaphthylen-1(5H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, DTXSID6045743, DTXCID4025743, API-2;NSC 154020;TCN, Triciribinum [INN-Latin], Triciribina [INN-Spanish], (2R,3R,4S,5R)-2-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)oxolane-3,4-diol, CAS-35943-35-2, CHEMBL331237, UNII-2421HMY9N6, Triciribine hydrate, NCGC00092314-01, NCGC00092314-04, API-2;Triciribine, 1,5-Dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylen-3-amine, BiomolKI2_000078, 1,4,5,6,8-Pentaazaacenaphthylene, 3-amino-1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-, SCHEMBL61268, TRICIRIBINE [WHO-DD], MLS006011145, EX-A415, GLXC-06824, HMS3413I03, HMS3677I03, Tox21_111192, BDBM50369528, MFCD16879015, NSC800957, s1117, AKOS024456958, Tox21_111192_1, CCG-100678, CS-0968, DB12405, NSC-800957, NT08796, SDCCGSBI-0053458.P007, 1,4,5,6,8-Pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-.beta.-D-ribofuranosyl-, 1,4,5,6,8-Pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-, NCGC00092314-02, NCGC00092314-06, AC-32686, HY-15457, SMR002530325, SRI-10809-03, NS00069245, BRD-K80431395-001-01-6, BRD-K80431395-001-04-0, BRD-K80431395-001-07-3, BRD-K80431395-001-09-9, Q25326616, 1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-dihydro-5-methyl-1-|A-D-ribofuranosyl-, 5-Methyl-1-beta-D-ribofuranosyl-1,5-dihydro-1,4,5,6,8-pentaazaacenaphthylen-3-amine, 6-Amino-4-methyl-8-(b-D-ribofuranosyl)4H,8H-pyrrolo[4,3,2-de]pyrimido[4,5-c] pyridazine, (2R,3R,4S,5R)-2-(5-amino-7-methyl-2,6,7,9,11-pentazatricyclo[6.3.1.04,12]dodeca-1(12),3,5,8,10-pentaen-2-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 3-AMINO-1,5-DIHYDRO-5-METHYL-1-.BETA.-D-RIBOFURANOSYL-1,4,5,6,8-PENTAAZAACENAPHTHYLENE
Theoretical properties:
molecular_formula: C13H16N6O4
molecular_weight: 320.30 g/mol
exact_mass: 320.12330301 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 8
rotatable_bond_count: 2
heavy_atom_count: 23
topological_polar_surface_area: 142 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Triciribine is a nucleoside analogue in which the nucleobase portion is a 1,4,5,6,8-pentaazaacenaphthylene ring system substituted with an amino group at position 3, and a methyl group at position 5 and is bound to the beta-D-ribofuranosyl moiety by an N1-glycosidic linkage. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor.
chebi: A nucleoside analogue in which the nucleobase portion is a 1,4,5,6,8-pentaazaacenaphthylene ring system substituted with an amino group at position 3, and a methyl group at position 5 and is bound to the β-D-ribofuranosyl moiety by an <em>N</em><small><sup>1</small></sup>-glycosidic linkage.
chembl: TRICIRIBINE is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: Triciribine is a cancer drug which was first synthesized in the 1970s and studied clinically in the 1980s and 1990s without success. Following the discovery in the early 2000s that the drug would be effective against tumours with hyperactivated Akt, it is now again under consideration in a variety of cancers. As PTX-200, the drug is currently in two early stage clinical trials in breast cancer and ovarian cancer being conducted by the small molecule drug development company Prescient Therapeutics.